Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study sheds light on breast cancer in transgender community

NCT ID NCT06234488

Knowledge-focused Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study gathers information from multiple hospitals about breast cancer in transgender and gender-diverse adults. Researchers want to understand how the cancer is found, what risk factors are involved, and how it is treated. The goal is to find ways to improve care and reduce differences in health outcomes for this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

125 people

The number who actually took part.

Started

Dec 2023

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible patients are those who had a breast cancer diagnosis (including those with ductal carcinoma in situ (DCIS), who were age ≥18 years at the time of diagnosis and identify as a gender and/or sex that is different from the sex they were assigned at birth (e.g., transgender, nonbinary, genderqueer, etc.) between 1/1/1990 - 7/1/2023.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years of age or older 2. Breast cancer diagnosis (including DCIS) 3. Persons who identify as gender and/or sex that is different from the sex they were assigned at birth Exclusion Criteria: 1. Age \<18 at time of breast cancer diagnosis 2. Cis-gendered persons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast adenocarcinoma breast cancer breast carcinoma in situ breast neoplasm ductal breast carcinoma in situ invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast adenocarcinoma Breast cancer Breast cancer in situ Breast cancer invasive Breast cancer stage Breast cancer stage IV Breast neoplasms

Contacts and locations

Locations

  • Birgham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Boston University (Boston U)

    Boston, Massachusetts, 02118, United States

  • Cleveland Clinic Foundation (CCF)

    Cleveland, Ohio, 44195, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • MedStar Georgetown University Hospital (MGUH)

    Washington D.C., District of Columbia, 20007, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Moffitt Cancer Center (MCC)

    Tampa, Florida, 33612, United States

  • New York University (NYU)

    New York, New York, 10012, United States

  • NorthShore University Health System

    Evanston, Illinois, 60201, United States

  • Northwestern Medicine

    Chicago, Illinois, 60611, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • University of California San Francisco (UCSF)

    San Francisco, California, 94115, United States

  • University of Colorado Anschutz Medical Campus (CU Anschutz)

    Aurora, Colorado, 80045, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Rochester

    Rochester, New York, 14623, United States

  • University of Southern California/Los Angeles (USC/LA County)

    Los Angeles, California, 90089, United States

  • University of Washington (UW)

    Seattle, Washington, 98195, United States

  • Vanderbilt University Medical Center (VUMC)

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.